Wednesday, November 5, 2025

The Triple Flexion Response in Friedrich’s Ataxia

›
Saluja A, Sahib A, Yadav V (November 04, 2025) The Triple Flexion Response in Friedrich’s Ataxia. Cureus 17(11): e96080. doi:10.7759/cureus....
Monday, November 3, 2025

Solid Biosciences Reports Third Quarter 2025 Financial Results

›
CHARLESTOWN, MA, Nov. 03, 2025 FA (SGT-212): Solid has activated the first clinical trial site and is currently screening participants for ...

Early experience on omaveloxolone in adult patients with Friedreich's ataxia: a real-world observational study

›
Lima SM, Caltagirone M, Messina C, Quartetti U, Rini N, D'Amico F, Brighina F, Di Stefano V. Early experience on omaveloxolone in adult ...
Sunday, November 2, 2025

Friedreich ataxia:

›
Subramony SH, Lynch DR. Friedreich Ataxia. Pediatr Neurol. 2025 Nov 1;174:148-154. doi: 10.1016/j.pediatrneurol.2025.10.020. Epub ahead of p...
Wednesday, October 29, 2025

Drivers of managed entry agreements to reduce reimbursement challenges of orphan medicinal products: the development of a matrix

›
Callenbach, M.H.E., van den Berg, S., Hulsbosch, A. et al. Drivers of managed entry agreements to reduce reimbursement challenges of orphan ...
Saturday, October 25, 2025

Positron emission tomography reveals increased myocardial glucose uptake in a subset of Friedreich ataxia patients

›
Payne, R.M., O’Connell, T.M., Pride, P.M. et al. Positron emission tomography reveals increased myocardial glucose uptake in a subset of Fri...

Development of an AAV-Based Gene Therapy for the Ocular Phenotype of Friedreich’s Ataxia

›
Tang H, Gupte S, Xu E, Calabro KR, Friend H, Crosson SM, Fajardo D,Kostamo Z, Zhang H, Peterson JJ, Lin F, Kozmik Z, Lutz CM, Boye SL, Boye ...
Friday, October 24, 2025

Neuropsychiatric challenges of Friedreich ataxia in a patient residing in a long-term care facility

›
Wong J, Kwok J, Kim K. Neuropsychiatric challenges of Friedreich ataxia in a patient residing in a long-term care facility. Prim Care Compan...
Thursday, October 23, 2025

Jupiter Neurosciences, Inc. strategic partnership with Zina Biopharmaceutica

›
October 22, 2025. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited dis...
Wednesday, October 22, 2025

Exploring the pleiotropic effects of lncRNA in different repeat expansion disorders

›
Soumalya Das, Shubhi Khandelwal, Sakshi Shukla, Amit Kumar, Exploring the pleiotropic effects of lncRNA in different repeat expansion disord...